Skip to main content
All lobbying filings

TODD STRATEGY GROUP

Lobbying for NOVARTIS, INC. · ​Multinational biopharmaceutical company.

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 17, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 5
  • PAUL EDATTEL
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • DANIEL M TODD
    Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
  • NICHOLAS UEHLECKE
    Previously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
  • ERIC BERGREN
    Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
  • NICOLAS MAGALLANES
    Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Health Issues

Supply Chain. 340B Issues. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.

Medicare/Medicaid

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.

Trade (domestic/foreign)

Tariffs.

 Bills named in this filing 6
  • H.R. 5376
    Impacts and Outcomes for Health Career Training Act
  • H.R. 1672
    Maintaining Investments in New Innovation Act
  • S. 3131
    ORPHAN Cures Act
  • H.R. 5539
    ORPHAN Cures Act
  • S. 832
    EPIC Act of 2025
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem